VY AADC

Drug Profile

VY AADC

Alternative Names: AAV-hAADC-gene-therapy - Voyager Therapeutics; AAV2-hAADC - Voyager Therapeutics; AV 201; GZ 404477; VY AADC01; VY AADC02

Latest Information Update: 13 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of California at San Francisco
  • Developer National Institutes of Health (USA); University of California at San Francisco; Voyager Therapeutics
  • Class Antiparkinsonians; Gene therapies
  • Mechanism of Action Dopamine release stimulants; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Parkinson's disease

Most Recent Events

  • 07 Aug 2018 Voyager Therapeutics announces intention to submit Biologics license application for Parkinson's disease
  • 18 Jul 2018 Voyager Therapeutics plans a phase III trial for Parkinson's disease
  • 28 Jun 2018 Phase-II clinical trials in Parkinson's disease in USA (Intrastriatal) (NCT03562494)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top